Transasia’s Make in India diagnostic instrument to help in affordable treatment of cancer patients

Transasia’s fully automated biochemistry analyzer, XL-1000 has been installed at the Mahamana Pandit Madanmohan Malaviya Cancer Center (MPMMCC), Varanasi, the second biggest cancer institute in India, inaugurated by the Prime Minister, Narendra Modi recently

0
75

Varanasi: The Prime Minister Narendra Modi has formally inaugurated the Mahamana Pandit Madanmohan Malaviya Cancer Center (MPMMCC) at Varanasi. The hospital has been set up to cater to the population of Uttar Pradesh and Bihar.

Mr Narendra Modi was taken through a guided tour of MPMMCC, led by Dr R. A. Badwe, Director- Tata Memorial Center (TMC), Mumbai, Dr Satyajit Pradhan, Deputy Director- MPMMCC; Dr Pankaj Chaturvedi, Dy. Director – Cancer Epidemiology, TMC.

While on his round of the facility, the Prime Minister also visited the biochemistry laboratory and inaugurated XL-1000, Transasia’s, Made in India, Fully Automated, Clinical Chemistry analyzer.

One of the most trusted in the clinical chemistry segment, XL-1000 is designed for high workload. With a capacity to conduct 1000 biochemical tests / hr, it is most suited for specialized institutes that have a requirement for testing of large number of samples. Infact, it is the first of its kind in Uttar Pradesh. XL-1000 is a result of Transasia’s in-house R&D efforts and indigenous manufacturing capabilities. With close to 200 installations across the globe and exported to more than 100 countries, it is considered the best in its category for the convenience it offers: quality, speed, accuracy and affordability.

The MPMMCC under the aegis of the reputed Tata Memorial Centre, Mumbai has been built at a cost of Rs 580 crores. Situated within the BHU campus, this 350- bedded ‘patient centric care’ facility, is expected to cater to the healthcare needs of about 40 lakhs patients from the city and nearby areas. The full fledged biochemistry laboratory at the hospital has been set up with joint efforts of Dr. Geeta Rathnakumar and Dr Pratibha Gavel.

The biochemistry laboratory was established and started under the guidance of Dr Sangeeta Desai, Prof. and Head, Pathology- Tata Memorial Hospital (TMH), Dr Nitin Inamdar, In-charge, Dept of Biochemistry, TMH by Dr. Geeta Rathnakumar, Lab Manager, Dept. of Biochemistry, TMH and Dr Pratibha Gavel, Asst. Prof. Biochemistry, HBCH and MPMMC.

Reacting on the need to set-up a cancer institute in Varanasi, Dr Satyajit Pradhan said, “Over the years, there has and continues to be an incremental rise in the incidence of cancer in Uttar Pradesh and Bihar. Infact, Varanasi is one of the hot zones, with a growing number of patients suffering from cancers of gall bladder, kidney, head and neck among others. Studies have revealed that the untreated wastes and domestic sewage that is let out in the Ganges, most likely contain environmental pollutants that are acting as carcinogens. Besides this people from the neighbouring villages and towns are addicted to tobacco and gutka, further leading to them succumbing to this deadly disease.”

He further added, “Interestingly the process for patient registration started even before the inauguration of the centre. In addition to the localities we are also expecting a lot of people belonging to the low socio-economic background from remote locations far and wide. While choosing the medical equipment for our facility, our main criteria was to select a company who could help us offer an analyzer of international quality standards, providing results in the most cost effective and timely manner. Being a Make in India product, we found Transasia’s XL-1000 along with environmentally friendly, economical consumables, to be the best suited for our centre. To add to that, its wide range of parameters that help in early and accurate diagnosis of cancer, its technical specifications, speed of reporting were all the criteria that we were looking for in an analyzer. We are most satisfied with Transasia’s long-standing repute of providing the best after-sales and technical service support.”

Suresh Vazirani, Chairman & Managing Director, Transasia Bio-Medicals said, “We are feeling a sense of great pride that our Make in India product XL-1000 has been inaugurated at  MPMMCC, the second biggest cancer institute in India, through the hands of the visionary of Make in India campaign. This cancer institute is a great initiative and I am sure it will be a big contributor to the Ayushman Bharat Scheme. XL-1000 is a fully automated analyzer with no manual intervention right from blood collection to report issuance, thereby ensuring accuracy and speed of reporting. A lot of patients, who will be coming to  MPMMCC from remote locations, can now go back with the results on the same day itself. Importantly, it offers a complete testing profile for the Heart, Liver and Renal Function Tests that are critical to early cancer diagnosis and evaluating the disease progression. Moreover, being locally manufactured equipment, we are able to ensure that we can offer cost-effective treatment to the patients, and contribute to the Ayushman Bharat Scheme.”

He further went on to say, “In the recently announced interim budget, the Government expressed its intent to set-up a National Artificial Intelligence portal to highlight the increasing role of technology in healthcare. XL-1000 infact offers integrated AI sensors and remote diagnosis technology that reduce the downtime and ensure uninterrupted service. Our dedicated team of six sales and service personnel in Varanasi is committed to offering technical and training support at all times.”